182 related articles for article (PubMed ID: 33843903)
1. Optimizing the treatment sequence from second-line to third-line therapy in patients with metastatic colorectal cancer.
Grothey A; Bekaii-Saab TS; Yoshino T; Prager GW
Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 2(1):1-24. PubMed ID: 33843903
[TBL] [Abstract][Full Text] [Related]
2. Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib.
Patel AK; Barghout V; Yenikomshian MA; Germain G; Jacques P; Laliberté F; Duh MS
Oncologist; 2020 Jan; 25(1):e75-e84. PubMed ID: 31591140
[TBL] [Abstract][Full Text] [Related]
3. Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland.
Siebenhüner A; De Dosso S; Meisel A; Wagner AD; Borner M
Oncol Res Treat; 2020; 43(5):237-244. PubMed ID: 32146471
[TBL] [Abstract][Full Text] [Related]
4. Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells.
Matsuoka K; Nakagawa F; Tanaka N; Okabe H; Matsuo K; Takechi T
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257515
[TBL] [Abstract][Full Text] [Related]
5. How to incorporate a chemo-free interval into the management of metastatic colorectal cancer.
Grothey A; Ciardiello F; Marshall JL
Clin Adv Hematol Oncol; 2020 Oct; 18 Suppl 16(10):1-24. PubMed ID: 33843848
[TBL] [Abstract][Full Text] [Related]
6. Improving survival in metastatic colorectal cancer through optimized patient selection.
Bekaii-Saab TS; Barzi A; Cusnir M
Clin Adv Hematol Oncol; 2024 Jun; 22 Suppl 4(5):1-20. PubMed ID: 38805297
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment.
Niisato Y; Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Shimada Y
Anticancer Res; 2021 Apr; 41(4):2203-2207. PubMed ID: 33813435
[TBL] [Abstract][Full Text] [Related]
8. A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer.
Moehler M; Michel M; Stein A; Trojan J; Marquardt J; Tintelnot J; Waidmann O; Weinmann A; Woerns MA; Schroeder H; Maenz M; Foerster F
Future Oncol; 2021 Sep; 17(25):3309-3319. PubMed ID: 33993741
[TBL] [Abstract][Full Text] [Related]
9. Sequencing considerations in the third-line treatment of metastatic colorectal cancer.
Barzi A; Bekaii-Saab T
Am J Manag Care; 2024 May; 30(2 Suppl):S31-S35. PubMed ID: 38701364
[TBL] [Abstract][Full Text] [Related]
10. Third-line treatments for the management of metastatic colorectal cancer: why to change the mechanism of action after frontline chemotherapy, and insights into management during the COVID-19 pandemic.
Marshall JL
Clin Adv Hematol Oncol; 2020 Oct; 18 Suppl 16(10):6-14. PubMed ID: 33843850
[No Abstract] [Full Text] [Related]
11. Transitioning from second-line to third-line therapy in metastatic colorectal cancer.
Marshall JL; Loupakis F; Bekaii-Saab TS
Clin Adv Hematol Oncol; 2021 Jan; 19 Suppl 3(1):1-20. PubMed ID: 33843898
[TBL] [Abstract][Full Text] [Related]
12. Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer.
Walter T; Hawkins NS; Pollock RF; Colaone F; Shergill S; Ross PJ
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2575-2587. PubMed ID: 32715436
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales.
Bullement A; Underhill S; Fougeray R; Hatswell AJ
Clin Colorectal Cancer; 2018 Mar; 17(1):e143-e151. PubMed ID: 29110922
[TBL] [Abstract][Full Text] [Related]
14. Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis.
Casadei-Gardini A; Vagheggini A; Gelsomino F; Spallanzani A; Ulivi P; Orsi G; Rovesti G; Andrikou K; Tamburini E; Scartozzi M; Cascinu S
Clin Colorectal Cancer; 2020 Jun; 19(2):82-90.e9. PubMed ID: 32192883
[TBL] [Abstract][Full Text] [Related]
15. Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review.
Arnold D; Prager GW; Quintela A; Stein A; Moreno Vera S; Mounedji N; Taieb J
Ann Oncol; 2018 Apr; 29(4):835-856. PubMed ID: 29452346
[TBL] [Abstract][Full Text] [Related]
16. Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.
Masuishi T; Taniguchi H; Kawakami T; Kawamoto Y; Kadowaki S; Onozawa Y; Muranaka T; Tajika M; Yasui H; Nakatsumi H; Yuki S; Muro K; Omae K; Komatsu Y; Yamazaki K
ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392174
[TBL] [Abstract][Full Text] [Related]
17. Salvage Therapy After Regorafenib or Trifluridine/Tipiracil Treatment of Metastatic Colorectal Cancer: A Conditional Landmark Analysis.
Nakashima M; Takeuchi M; Tanaka S; Kawakami K
Anticancer Res; 2021 Feb; 41(2):1055-1062. PubMed ID: 33517315
[TBL] [Abstract][Full Text] [Related]
18. Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan.
Ogata M; Kotaka M; Ogata T; Hatachi Y; Yasui H; Kato T; Tsuji A; Satake H
PLoS One; 2020; 15(6):e0234314. PubMed ID: 32530932
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis.
Basso M; Signorelli C; Calegari MA; Lucchetti J; Zurlo IV; Dell'Aquila E; Arrivi G; Zoratto F; Santamaria F; Saltarelli R; Trovato G; Caira G; Angotti L; Schirripa M; Anghelone A; Schietroma F; Chilelli MG; Salvatore L; Pozzo C; Tortora G
Target Oncol; 2024 May; 19(3):371-382. PubMed ID: 38613732
[TBL] [Abstract][Full Text] [Related]
20. Trifluridine/tipiracil or regorafenib in refractory metastatic colorectal cancer: from clinical trials to daily clinical practice.
Giuliani J; Insolda J; Pigozzi E; Bonetti A
Recenti Prog Med; 2020 Dec; 111(12):785-787. PubMed ID: 33362177
[No Abstract] [Full Text] [Related]
[Next] [New Search]
